PAPER

View Article Online
View Journal | View Issue Cite this: *RSC Adv.*, 2017, 7, 8866

Synthesis and biological evaluation of terminal functionalized thiourea-containing dipeptides as antitumor agents†

Ri-Zhen Huang,^{‡,ab} Bin Zhang,^{‡,a} Xiao-Chao Huang,^b Gui-Bin Liang,^a Jian-Mei Qin,^a Ying-Ming Pan,^a Zhi-Xin Liao^{*b} and Heng-Shan Wang^{*a}

A series of antitumor agents based on terminal functionalized dipeptide derivatives containing the thiourea moiety were synthesized and evaluated for antiproliferative activity using a panel of cancer cell lines, and the effects and mechanism of apoptosis induction were determined. These compounds exhibited significant selectivity to different cancer cell lines with IC₅₀ values at micromolar concentrations. In particular, compound **I-11** appeared to be the most potent compound, with an IC₅₀ = 4.85 ± 1.44 μM against the NCI-H460 cell line, at least partly, by the induction of apoptosis. Mechanistically, compound **I-11** induced the activation of caspase-12 and CHOP, which triggered apoptotic signalling via the ROS-dependent endoplasmic reticulum pathway and arrested the cell cycle at the S phase. Thus, we concluded that dipeptide derivatives containing the thiourea moiety terminally functionalized by electron-withdrawing substituents may be potential antitumor agents for further investigation.

Received 21st October 2016

Accepted 11th January 2017

DOI: 10.1039/c6ra25590f

www.rsc.org/advances

1 Introduction

Peptides are among the most versatile bioactive molecules and play crucial roles in the human body and other organisms.¹ Because of their good solubility, permeability and bioavailability, many peptide hormones and analogous short peptides exert their action by binding to membrane receptors,^{2,3} or possess signaling and regulatory functions.⁴ Accordingly, the potential applications of these peptide-like structures are legion and become immediately apparent. Recently, several peptide-based derivatives have been in clinical trials, including bortezomib,⁵ carfilzomib,⁶ DLS-10 (ref. 7) and ixazomib⁸ (Fig. 1). Encouraged by these research results, our interest in investigating peptide-based drugs for their potential therapeutic effects has recently spurred us to examine the influences of dipeptide derivatives on antitumor properties.

Previous work has indicated that dipeptides and their derivatives, in addition to enzyme inhibitors or drug carriers, exhibit a wide spectrum of important bioactivities such as antimicrobial, neuroprotective, antiviral and anticancer activities.^{9–11} In particular, anticancer peptides have shown relevant

potency since they exhibit cancer selective toxicity while avoiding the shortcomings of the conventional chemotherapy.¹² Modern studies have also indicated that dipeptides as well as their analogs exhibit anticancer activity in many human cancer cells such as colon, gastric, cervical and breast cancer cells.^{13–16} However, most of the natural peptides consist of the L-form α amino acids and due to the ubiquitous prevalence of peptidases, they exhibit limited biostability, and consequently, low bioavailability.¹⁷ The inability to cross epithelial layers, including the blood–brain barrier, side effects and drug resistance remain the major clinical challenges. Due to these limitations, the development of pseudopeptides could lead to many pharmacokinetic and pharmacodynamic advantages. This strategy can be realized by introducing unnatural amino acids instead of natural residues into the peptide framework, or by the introduction of a non-peptidic scaffold into the peptidic backbone, to lock a defined conformation of the peptide.^{18,19} These novel compounds provide new perspectives in drug design by providing an entire range of highly specific and non-toxic pharmaceuticals. Several non-peptidic skeletons have been thus conjugated with peptides, and such analogs as conjugates of paclitaxel, doxorubicin and daunorubicin with an amino acid or peptides have demonstrated increased and more selective anticancer activity than the drugs themselves.^{20–26}

Among the anti-tumor drugs discovered in recent years, thiourea derivatives^{27,28} possess potent anticancer properties. Thiourea derivatives display a wide range of biological activity including antibacterial, anti-fungal, antiviral, anthelmintic, antituberculosis, and plant growth regulator properties.^{29–32} In addition to increased stability, the incorporation of a thiourea

^aState Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Yucui Road 15, Guilin 541004, Guangxi, PR China. E-mail: whengshan@163.com

^bPharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China. E-mail: zxliao@seu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra25590f

‡ These authors contributed equally to this work.

Fig. 1 Chemical structures of peptide-based derivatives for clinical use.

moiety into the peptide sequence also provides access to additional binding interactions within the transition state conformation of the enzyme/substrate complex.^{33,34} Thiourea could strongly enhance blocking, since sulfur is the weaker hydrogen bond acceptor as compared to the amide carbonyl oxygen, and simultaneously enhance hydrogen-bonding due to the bidentate binding mode of the more acidic thiourea protons.^{35,36} Herein, we designed and synthesized a series of dipeptide thiourea derivatives as antitumor drugs. Their *in vitro* cytotoxicities against five selected tumor cell lines were evaluated. Moreover, the molecular mechanism of apoptosis in NCI-H460 cells by the representative target compound **I-11** was also investigated.

2 Results and discussion

2.1 Chemistry

The general procedures for the synthesis of functionalized dipeptide thioureas are shown in Scheme 1. First, Boc-amide and aniline derivatives underwent acylation and deprotection, and each amino acid was sequentially coupled to the peptide chain from the C- to N-terminus in the presence of HOBT, EDCI and Et₃N. After obtaining the free amine dipeptide **H** by the removal of the protective group, target compounds **I** were synthesized by the condensation of phenylisothiocyanate, according to a previously published report,³⁷ with **H** in DCM at room temperature. The structures of target compounds **I** were then confirmed by ¹H NMR, ¹³C NMR and high resolution mass spectrometry (HRMS).

2.2 Biology activity

2.2.1 Cytotoxicity test. The *in vitro* cytotoxicity of the synthesized compounds was evaluated by the methylthiazol tetrazolium (MTT) assay in a panel of five human cancer cell lines, including MGC-803 human gastric cancer cells, NCI-H460 human lung cancer cells, HepG-2 human liver cancer cells,

Hct-116 human colon tumor cells, and SKOV-3 human ovarian cancer cells. The commercial anticancer drugs 5-fluorouracil (5-FU) and ubenimex (Ube) were positive controls. The assay results are shown in Table 1, where we see that most of the test compounds exhibited moderate to high inhibitory activity against the tested tumor cell lines, indicating that the introduction of the thiourea moiety on the dipeptide could improve anti-tumor activity. Compounds **I-10**, **I-11** and **I-32** showed good inhibitory activity for all the tested carcinoma cell lines. Compound **I-9** showed strong inhibitory activity selectivity for MGC-803, as well as NCI-H460; **I-31** showed selectivity for NCI-H40, and **I-25** showed selectivity for MGC-803. The others also showed good inhibitory activity, except **I-8**, **I-16**, **I-17**, **I-30**, **I-33**, **I-34**, for the tested carcinoma cell lines. In particular, compound **I-11** showed noteworthy anti-cancer activity *in vitro*, with IC₅₀ value of 4.85 μM against NCI-H460. The results revealed that the analogs **I-11**, **I-25**, **I-31** and **I-32**, obtained by inserting the trifluoromethyl or halogen moiety in positions R₁ and R₂ of the benzene ring, significantly increased anti-proliferative potencies. For example, compound **I-25**, with IC₅₀ value of 9.13 μM, was more active than derivatives **I-24** and **I-26**, and undoubtedly emerged as one of the most active compounds within this subset, thus suggesting that the insertion of electron-withdrawing groups in positions R₁ and R₂ may have resulted in certain steric electronic properties that enhanced lipophilicity and the ability to penetrate the cellular membrane, leading to an increased antiproliferative effect. On the other hand, the presence of a weakly electron-withdrawing substituent in positions R₁ and R₂ is harmful to the antiproliferative effect: the derivatives **I-33** and **I-34** were not active against the tested cell lines. A slight beneficial effect was also observed with the modifications of the R₃ and R₄ positions: the derivative **I-11** was more active than **I-32**. It is also important to note that the R₁ and R₂ substitutions seem more important for cytotoxicity than R₃ or R₄ substitutions, since the variation of R₃ or R₄ slightly changed the potency. These interesting results may indicate

Scheme 1 General synthetic route for compound I.

that these compounds exert their antitumor activities by targeting different protein targets or signal pathways. The presence of a bulky group in position R₃ and R₄ seems to be associated with a general increase in activity. In addition, the inhibition activities of compounds **I** against HUVEC normal cell lines were also estimated in Table 1. The results indicated that the cytotoxicity of most of the compounds against cancer cells was much higher than the HUVEC normal cells, as compared to 5-FU and Ube, making them good candidates for anti-tumor drugs.

2.2.2 Cell cycle analysis. To determine the possible role of cell cycle arrest in dipeptide thiourea derivative-induced growth inhibition, NCI-H460 cells were treated with different

concentrations of compound **I-11**. Cell cycle distribution was investigated by flow cytometric analysis following staining of DNA with propidium iodide (PI). After treatment with compound **I-11** at different concentrations for 48 h, it was observed that G1 phase cells gradually decreased and G2 phase cells did not change significantly, while S phase cells, compared with the control cells, gradually increased (Fig. 2 and 3). These results suggest that target compound **I-11** mainly arrested NCI-H460 cells in the S phase.

2.2.3 Compound I-11 induces apoptosis in NCI-H460 cells.

In order to confirm whether **I-11**-induced reduction in cell viability was responsible for the induction of apoptosis, NCI-H460 cells were co-stained with PI and Annexin-V FITC, and

Table 1 IC₅₀ values (μM) of functionalized dipeptide thiourea derivatives I towards five selected tumor cell lines and normal cell lines, for 48 h

I

Compd	IC ₅₀ ^a (μM)					
	MGC-803	NCI-H460	Hct-116	HepG-2	SKOV-3	HUVEC
I-1	25.82 ± 1.12	23.11 ± 1.22	29.34 ± 1.07	27.16 ± 1.16	24.58 ± 0.91	>50
I-2	24.51 ± 0.83	24.32 ± 1.29	26.17 ± 1.01	29.05 ± 0.96	29.96 ± 0.87	>50
I-3	40.01 ± 0.86	38.37 ± 0.93	39.25 ± 1.14	41.27 ± 1.02	44.32 ± 1.11	>50
I-4	20.85 ± 1.06	21.39 ± 0.99	21.06 ± 0.98	26.79 ± 1.10	28.28 ± 0.89	>50
I-5	30.43 ± 1.00	31.20 ± 1.04	27.77 ± 0.94	34.57 ± 0.85	30.99 ± 1.35	>50
I-6	38.95 ± 0.71	39.48 ± 1.25	38.62 ± 0.68	42.07 ± 1.18	39.24 ± 0.49	>50
I-7	26.38 ± 1.21	25.41 ± 1.33	30.17 ± 0.90	30.95 ± 1.23	31.84 ± 0.75	>50
I-8	>50	>50	>50	>50	>50	>50
I-9	8.92 ± 1.02	9.55 ± 0.46	10.70 ± 0.85	12.31 ± 1.13	13.60 ± 1.08	>50
I-10	7.49 ± 1.06	13.06 ± 1.19	9.13 ± 1.11	13.70 ± 0.92	10.36 ± 1.04	>50
I-11	8.26 ± 1.27	4.85 ± 1.44	8.92 ± 1.26	10.88 ± 1.05	10.86 ± 1.14	>50
I-12	33.05 ± 1.05	30.29 ± 1.42	38.47 ± 0.84	37.21 ± 1.15	>50	>50
I-13	12.53 ± 1.21	14.65 ± 0.74	19.82 ± 0.89	13.82 ± 1.03	23.27 ± 1.32	>50
I-14	12.27 ± 1.18	17.89 ± 1.13	22.51 ± 0.74	21.28 ± 0.76	21.24 ± 1.24	>50
I-15	30.45 ± 1.28	41.29 ± 1.15	36.71 ± 0.64	33.22 ± 1.31	42.36 ± 0.82	>50
I-16	>50	>50	>50	>50	>50	>50
I-17	>50	>50	>50	>50	>50	>50
I-18	38.21 ± 1.09	41.89 ± 0.97	46.61 ± 1.03	38.95 ± 1.19	42.48 ± 0.99	>50
I-19	16.73 ± 0.86	14.95 ± 0.59	16.43 ± 1.08	20.13 ± 1.16	15.98 ± 1.51	>50
I-20	18.79 ± 1.14	18.51 ± 0.88	20.83 ± 0.98	24.45 ± 1.27	22.78 ± 0.87	>50
I-21	16.47 ± 0.97	15.63 ± 0.58	20.73 ± 1.21	19.44 ± 0.95	20.81 ± 1.47	>50
I-22	17.15 ± 1.26	17.31 ± 1.31	19.86 ± 1.29	21.86 ± 1.18	19.35 ± 1.53	>50
I-23	17.52 ± 1.22	17.66 ± 1.23	18.59 ± 1.34	21.05 ± 1.28	20.24 ± 1.45	>50
I-24	37.98 ± 1.03	40.82 ± 1.79	41.55 ± 1.25	40.79 ± 0.71	46.43 ± 1.33	>50
I-25	9.13 ± 1.09	10.62 ± 1.14	12.74 ± 1.17	14.32 ± 1.20	13.82 ± 1.02	>50
I-26	35.48 ± 0.83	31.67 ± 1.49	34.83 ± 1.13	36.24 ± 1.21	39.40 ± 1.36	>50
I-27	29.22 ± 0.76	28.80 ± 1.37	30.76 ± 1.04	31.81 ± 1.26	32.49 ± 0.62	>50
I-28	34.37 ± 1.09	32.46 ± 1.06	37.63 ± 1.16	38.24 ± 0.91	37.38 ± 1.20	>50
I-29	28.25 ± 1.11	29.58 ± 1.28	30.48 ± 0.78	31.65 ± 0.88	32.10 ± 1.51	>50
I-30	>50	>50	>50	>50	>50	>50
I-31	13.75 ± 1.23	9.93 ± 1.36	11.59 ± 0.94	15.09 ± 1.17	10.26 ± 0.96	>50
I-32	8.79 ± 0.77	7.93 ± 1.05	13.78 ± 1.15	10.16 ± 0.84	11.62 ± 1.08	>50
I-33	>50	>50	>50	>50	>50	>50
I-34	>50	>50	>50	>50	>50	>50
I-35	41.65 ± 1.02	39.07 ± 1.34	42.69 ± 0.36	41.78 ± 1.04	40.57 ± 0.61	>50
I-36	42.93 ± 1.36	44.86 ± 1.17	>50	>50	>50	>50
5-FU	46.92 ± 2.03	44.05 ± 0.64	23.50 ± 2.34	30.98 ± 0.73	27.23 ± 0.16	56.00 ± 1.45
Ube	>50	>50	>50	>50	>50	>50

^a IC₅₀ values are presented as the mean ± SD (standard error of the mean) from three separated experiments.

the number of apoptotic cells was estimated by flow cytometry (Fig. 4). Four quadrant images were observed by flow cytometric analysis: the Q1 area represented damaged cells that appeared during the process of cell collection; the Q2 region showed necrotic cells and later stage apoptotic cells; early apoptotic cells were located in the Q3 area, and the Q4 area showed normal cells. A dose-dependent increase in the percentage of apoptotic cells was noted after the cells were treated with compound I-11 at the concentrations of 5 μM, 10 μM and 15 μM for 24 h. As shown in Fig. 4 and 5, few (4.79%) apoptotic cells

were present in the control panel; in contrast, the percentage rose to 19.35% at the concentration of 5 μM after treatment with I-11 for 24 h. At concentrations of 10 μM and 15 μM, there was a further increase to 42.3% and 43.4% after treatment with I-11, respectively. These results clearly confirm that compared with the control, compound I-11 effectively induced apoptosis in NCI-H460 cells in a dose-dependent manner.

2.2.4 Morphological characterization of NCI-H460 cell apoptosis by Hoechst 33258. In order to further validate cell apoptosis following treatment with compound I-11, NCI-H460

Fig. 2 Investigation of cell cycle distribution of compound **I-11** by flow cytometric analysis. (a) Untreated NCI-H460 cells as a control. (b, c, and d) Cells were treated with increasing concentrations of compound **I-11** (2 μ M, 4 μ M and 8 μ M) for 48 h, respectively.

cells treated with compound **I-11** at 10 μ M from 6 to 24 h were stained with Hoechst 33258. Control cells exhibited weak blue fluorescence (Fig. 6a); following treatment with compound **I-11**, some cells emitted brilliant blue fluorescence, and the nuclei of NCI-H460 cells appeared hyper-condensed (brightly stained). The number of apoptotic nuclei containing condensed chromatin increased significantly when NCI-H460 cells were treated with compound **I-11** for 24 h, indicating that apoptosis of NCI-H460 cells was induced by compound **I-11** in a time-dependent manner.

2.2.5 Compound I-11 induces release of intracellular calcium. Conditions such as drug treatment, which interfere with ER function and induced endoplasmic reticulum (ER) stress and swelling, causing cavities or the accumulation of unfolded proteins in the ER or misfolded proteins, play a crucial role in the ER stress-related protein degradation pathway.³⁸ The ER is the primary storage site for intracellular calcium, and pumps in the ER membrane maintain a calcium gradient $\sim$ 1000-fold higher than that in the cytoplasm.³⁹ To determine whether **I-11** induced the release of intracellular calcium in NCI-H460 cells, the calcium level was measured with and without (control) **I-11** (10 μ M) treatment for 6 to 24 h, using the fluorescent probe fluo-3-acetoxymethyl-ester (Fluo-3/AM) and flow cytometry. In the control cells, the level of intracellular calcium was lowest (Fig. 7). Treatment of NCI-H460 cells with compound

I-11 increased the level of intracellular calcium within 6 h of treatment, and the highest level of intracellular calcium was observed after treatment for 24 h. Therefore, these findings indicate that compound **I-11** can significantly increase the intracellular level of calcium released.

2.2.6 Compound I-11 disrupts mitochondrial membrane potential. Cytoplasmic calcium is rapidly taken up by the mitochondria resulting in mitochondrial swelling and loss of mitochondrial membrane potential (MMP).³⁹ The loss of MMP is regarded as a limiting factor in the apoptotic pathway. In order to further investigate the antiproliferative effect of target compound **I-11**, changes in MMP were detected using the fluorescent probe JC-1, which exhibits potential dependent accumulation in mitochondria, indicated by a fluorescence emission shift from red ($\sim$ 590 nm) to green ($\sim$ 545 nm). In the control cells, JC-1 aggregated in the mitochondria and showed strong red fluorescence. However, in cells undergoing apoptosis, where the mitochondrial potential had collapsed, JC-1 was located in the cytosol as a monomer and emitted green fluorescence. NCI-H460 cells treated with compound **I-11** at 10 μ M from 6 to 24 h were stained with JC-1 for 24 h and cells not treated with compound **I-11** were used as controls.

The results are shown in Fig. 8. The JC-1 monomer and J-aggregates were excited at 514 nm and 585 nm, respectively, and light emissions were collected at 515–545 nm (green) and 570–600 nm (red). Fluorescence microscopy (Fig. 8) showed that cells not treated with compound **I-11** were normally red (in the web version), while cells treated with **I-11** showed strong yellow-green fluorescence and typical apoptotic morphology after 6 h, 12 h and 24 h, suggesting the occurrence of mitochondrial depolarization by **I-11**.

2.2.7 Compound I-11 triggers ROS generation. Reactive oxygen species (ROS) are highly harmful to cells as they initiate oxidative stress and ultimately cause cellular damage. Excessive ROS generation renders cells vulnerable to apoptosis.⁴⁰ To determine whether **I-11** triggers ROS generation in NCI-H460 cells to induce apoptosis, the ROS level was measured with and without (control) **I-11** (10 μ M) treatment for 6 to 24 h, using the fluorescent probe 2,7-dichlorofluorescein diacetate (DCF-DA) and flow cytometry. As shown in Fig. 9, compound **I-11** induced an increase in ROS levels in NCI-H460 cells. After exposure to 10 μ M of compound **I-11** for 24 h, the ROS level was 42.6%, which was more than three times that of the control. Taken together, these results show that **I-11** caused oxidative

Fig. 3 The percentages of NCI-H460 cells in different phases of cell cycle are presented.

Fig. 4 Apoptosis ratio detection of compound I-11 by Annexin V/PI assay. (a) NCI-H460 cells not treated with I-11. (b, c, and d) NCI-H460 cells treated with compound I-11 at 5 μ M, 10 μ M and 15 μ M for 24 h, respectively.

imbalance in NCI-H460 cells. This induction of oxidative burst is a key factor in the antiproliferative activity of compound I-11.

2.2.8 Compound I-11 induces eIF2 α phosphorylation. In general, ER stress removes proteins accumulated in the ER and promotes cell survival by inhibiting protein synthesis, while overload or sustained ER stress induces cell death through a series of signaling pathways, including the CHOP pathway, IRE1 α -ASK1-JNK pathway and Caspase-12 pathway.³⁸ The pancreatic ER kinase (PKR)-like ER kinase (PERK), a trans-membrane protein kinase in the ER stress signaling network, was previously shown to phosphorylate eIF2 α in response to ER stress. The activation of PERK also leads to the induction of CHOP, which, as detailed later, is an important element in the switch from pro-survival to pro-death signaling. To further investigate the molecular mechanism of compound I-11 against NCI-H460 cells to gain further insight into its mode of action,

we monitored the changes in apoptotic molecules related to the ER stress signaling pathway. A number of key protein markers involved in this signaling network were also examined by western blot analysis. As shown in Fig. 10a, treatment of NCI-H460 cells with I-11 caused a significant increase in the levels of GRP78 and CHOP, in a dose-dependent manner. Furthermore, in comparison with the control cells, compound I-11 induced eIF2 α and PERK phosphorylation.

2.2.9 Activation of caspases. Intracellular calcium plays a central role in the regulation of calpain activity.⁴¹ It is known that calcium-activated calpain can cleave cellular proteins, which results in cell swelling, membrane rupture, and cell death. Calpain and caspase are cysteine proteases and have important roles in the initiation, regulation and execution of cell death such as apoptosis and necrosis.⁴² As illustrated in Fig. 10b, calcium overload was observed in NCI-H460 cells

Fig. 5 Populations of apoptotic NCI-H460 cells treated with increasing concentrations of compound I-11 (5 μ M, 10 μ M and 15 μ M) obtained by FACS analysis with PI and FITC-Annexin V staining.

following treatment with compound I-11; therefore, we hypothesized that elevated caspase-12/caspase-4 and calpain activity may be triggered by calcium overload. As shown in Fig. 10b, target compound I-11 caused a significant time-dependent induction of caspase-12 and caspase-4 expression. In addition, we also demonstrated that treatment with compound I-11 significantly activated the downstream death receptor cascade, as evidenced by increased caspase-9 levels in the cytoplasm, which may further amplify mitochondrial membrane permeability.

Fig. 7 Effects of compound I-11 on the intracellular free Ca^{2+} levels in NCI-H460 cells. After treatment with compound I-11 (10 μ M) for 6 h, 12 h and 24 h, respectively, NCI-H460 cells stained with Fluo-3AM for 30 min were analyzed by flow cytometry.

3 Conclusion

A series of dipeptide thiourea derivatives were designed and synthesized as potential antitumor agents with high selectivity. These compounds exhibited significant selectivity against different cancer cell lines with IC_{50} values at micromolar concentrations. It is noteworthy that further antitumor activity screening revealed that some compounds exhibited better

Fig. 6 Hoechst 33258 staining of compound I-11 in NCI-H460 cells. (a) Cells not treated with compound I-11 were used as control. (b, c, and d) Treatment with compound I-11 (10 μ M) for 6 h, 12 h and 24 h, respectively.

Fig. 8 JC-1 staining of compound I-11 in NCI-H460 cells. (a) Cells not treated with compound I-11 were used as control. (b, c, and d) Treatment with compound I-11 (10 μ M) for 6 h, 12 h and 24 h, respectively.

inhibitory activity than the commercial anticancer drug 5-Fu and Ube. In particular, compound **I-11** ($IC_{50} = 4.85 \pm 1.44 \mu$ M) exhibited the best anticancer activity against the NCI-H460 cell line and displayed more potent inhibitory activity than 5-Fu and Ube. The apoptosis-inducing activity of representative compound **I-11** in NCI-H460 cells was investigated by Hoechst 33258 staining, JC-1 mitochondrial membrane potential staining, and flow cytometry. Simultaneous molecular mechanism studies suggested that target compound **I-11** induced apoptosis in NCI-H460 cells through induction of ER stress-reactive oxygen species. Furthermore, cell cycle analysis indicated that compound **I-11** arrested the NCI-H460 cell line in the S phase. The possible mechanism involved in compound **I-11** induced apoptosis is shown in Fig. 11. Consequently, the rational design of dipeptide thiourea derivatives offers significant potential for the discovery of a new class of antitumor agents. The precise mechanism of this action requires further investigation.

4 Experimental

4.1 General information

The isothiocyanate was synthesized according to the literature.³⁴ Compound **H** was synthesized according to the literature.⁴³ All the chemical reagents and solvents used were of analytical grade. Aniline derivatives and all N-Boc protection amino acids during the synthesis were commercially available and purchased from Aladdin and Energy Chemical. Silica gel (300–400 mesh) used in column chromatography was provided by Tsingtao Marine Chemistry Co. Ltd. Precoated silica gel plates F-254 were used for thin-layer analytical chromatography.

1 H-NMR and 13 C-NMR spectra were recorded on a Bruker AMX-400 and AMX-500 spectrometer. High-resolution mass spectra (HRMS) were recorded using ESI and APCI ionization sources.

4.2 Experimental section

4.2.1 General procedure for isothiocyanate compounds.

Toluene (20 mL) was added to the amine (10 mmol) and Et_3N (30.3 mmol). CS_2 (30.3 mmol) was added while stirring, resulting in the precipitation of the dithiocarbamate. The reaction mixture was stirred for 9 h at room temperature and then filtered and dried. The resulting powder was suspended in the CH_2Cl_2 (20 mL), and cooled to 0 $^{\circ}C$ and then BTC (3.3 mmol) was added. After completing the reaction at room temperature for 1 h, refluxing was continued for 2 h. Insolubles were removed by filtration, and the solvent was purified by chromatography on silica gel eluted with petroleum ether to offer isothiocyanate.

4.2.2 General procedure for compounds C and F.

To a stirred solution of *N*-*t*-butyloxycarbonyl-L-amino (5.5 mmol) in DMF (10 mL), was added Et_3N (12.5 mmol) and HOBT (7.5 mmol). The mixture was allowed to stir for 1 h and then cooled to 0 $^{\circ}C$ and then EDCI (7.5 mmol) was added. After 1 h, a solution of aniline derivatives (5 mmol) in DMF (10 mL) was added to the above reaction mixture. The resulting mixture was stirred for 7 h at room temperature. After completion as monitored by TLC, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with saturated brine solution, followed by drying over Na_2SO_4 and evaporating *in vacuo*. The crude product was purified by column

Fig. 9 ROS generation assay of compound I-11 in NCI-H460 cells. (a) Cells not treated with I-11 were used as the control for 24 h. (b, c, and d) Treatment with compound I-11 (10 μM) for 6 h, 12 h and 24 h, respectively.

chromatography (EtOAc/petroleum ether) to give the pure intermediates C and F.

4.2.3 General procedure for compounds D and H. To a round flask was added C or F and a standard 50% TFA/CH₂Cl₂. The sample was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the residue was partitioned between NaHCO₃ and EtOAc. The solvent of the organic layer was removed under reduced pressure. The residue thus obtained was purified by column chromatography (EtOAc/petroleum ether) to give the deprotection of the Boc group to unmask the free amine D and H.

4.2.4 General procedure for compounds I. Compounds I were obtained by the condensation of isothiocyanates with F in CH₂Cl₂ at room temperature. The structures were confirmed by ¹H NMR, ¹³C NMR and HR-MS (see ESI†). The spectral data for the representative compounds are shown in detail.

1-(1-(1-(2,5-Dimethoxyphenylamino)-1-oxo-3-phenylpropan-2-ylamino)-3-methyl-1-oxopentan-2-yl)-3-(3-nitrophenyl)thiourea (I-1). Yield 77.4%. Mp 187.5–190.1 °C. [α]_D²⁰ = −29.2 (c 0.1, AcOEt). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.15 (s, 1H), 9.06 (s, 1H), 8.84 (s, 1H), 8.61 (d, *J* = 7.9 Hz, 1H), 7.97 (d, *J* = 8.5 Hz, 1H), 7.92 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.83 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.73 (d, *J* = 2.7 Hz, 1H), 7.58 (t, *J* = 8.2 Hz, 1H), 7.33 (d, *J* = 7.3 Hz, 2H), 7.23 (t, *J* = 7.4 Hz, 2H), 7.16 (d, *J* = 7.3 Hz, 1H), 6.94 (d, *J* = 9.0 Hz, 1H), 6.62 (dd, *J* = 8.9, 3.0 Hz, 1H), 5.00–4.90 (m, 1H), 4.82 (dd, *J* = 13.0, 8.7 Hz, 1H), 3.76 (s, 3H), 3.68 (s, 3H), 3.15 and 2.96 (dd, *J* = 13.9, 4.7 Hz, 1H; dd, *J* = 13.8, 9.7 Hz, 1H), 1.90–1.80 (m, 1H), 1.44 and 1.08 (ddd, *J* = 13.1, 7.4, 3.1 Hz, 1H; td, *J* = 13.7, 8.2 Hz, 1H), 0.91–0.73 (m, 6H, 2 × CH₃). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 180.4, 170.9, 169.7, 152.9, 147.5, 143.1, 141.0, 137.6, 129.7, 129.3, 129.3, 128.0, 128.0, 127.8, 126.2, 117.9, 115.9, 111.8, 108.0, 107.5, 60.9, 56.2, 55.3, 55.3, 54.9, 37.5, 36.7, 24.3, 15.1,

Fig. 10 Western blotting analysis effect of compound I-11 on the expression of (b) caspase-9, caspase-3, caspase-12, calpain, caspase-4, (a) CHOP, GRP78, p-PERK and p-eIF2α in NCI-H460 cells. NCI-H460 cells were treated with compound I-11 at 10 μM for 6 h, 12 h and 24 h, respectively. Equal amounts of protein were loaded on SDS-PAGE gel for western blot analysis as described in the experimental section. β-Actin was used as an internal control.

Fig. 11 The signaling pathways for apoptosis and cell cycle arrest induced by compound I-11.

11.3. ESI-HRMS m/z calcd for $C_{30}H_{35}N_5O_6S$ $[M + H]^+$: 594.2381; found: 594.2355.

1-(3-Chlorophenyl)-3-(1-(1-(4-methoxyphenylamino)-1-oxo-3-phenylpropan-2-ylamino)-3-methyl-1-oxopentan-2-yl)thiourea (I-5). Yield 76.5%. Mp 169.9–173.5 °C. $[\alpha]_D^{20} = -27.0$ (c 0.1, AcOEt).

1H NMR (400 MHz, DMSO- d_6) δ 9.92 (s, 1H), 9.74 (s, 1H), 8.35 (d, $J = 8.0$ Hz, 1H), 7.96 (s, 1H), 7.83 (d, $J = 8.1$ Hz, 1H), 7.46 (d, $J = 8.9$ Hz, 2H), 7.35 (dd, $J = 10.3, 8.1$ Hz, 2H), 7.29 (d, $J = 7.0$ Hz, 2H), 7.24 (t, $J = 7.4$ Hz, 2H), 7.17 (d, $J = 7.1$ Hz, 1H), 7.13 (d, $J = 7.4$ Hz, 1H), 6.87 (d, $J = 9.0$ Hz, 2H), 4.85 (d, $J = 6.5$ Hz, 1H), 4.70 (dd, $J = 13.9, 8.4$ Hz, 1H), 3.72 (s, 3H), 3.09 and 2.95 (dd, $J = 13.8, 5.2$ Hz, 1H; dd, $J = 13.7, 9.3$ Hz, 1H), 1.83 (d, $J = 6.1$ Hz, 1H), 1.39 and 1.11–0.97 (dd, $J = 11.9, 5.6$ Hz, 1H; m, 1H), 0.82 (d, $J = 7.8$ Hz, 6H, $2 \times CH_3$). ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.3, 170.5, 169.1, 155.4, 141.2, 137.6, 132.5, 131.8, 130.0, 129.2, 129.2, 128.0, 128.0, 126.3, 123.4, 121.4, 121.4, 121.0, 120.4, 113.8, 113.8, 61.2, 55.1, 54.7, 37.5, 37.4, 24.4, 15.2, 11.4. ESI-HRMS m/z calcd for $C_{29}H_{33}ClN_4O_3S$ $[M - H]^-$: 551.1889; found: 551.1903.

N-(1-Oxo-3-phenyl-1-((3-(trifluoromethyl)phenyl)amino)propan-2-yl)-3-phenyl-2-(3-(3-(trifluoromethyl)phenyl)thiourea)propanamide (I-11). Yield 78.3%. Mp 143.8–150.6 °C. $[\alpha]_D^{20} = -26.0$ (c 0.1, AcOEt). 1H NMR (500 MHz, DMSO- d_6) δ 10.45 (s, 1H), 10.15 (s, 1H), 8.80 (d, $J = 7.8$ Hz, 1H), 8.10 (s, 2H), 7.85 (d, $J = 7.5$ Hz, 1H), 7.80 (d, $J = 8.4$ Hz, 1H), 7.59 (dd, $J = 17.8, 9.0$ Hz, 2H), 7.50 (t, $J = 7.9$ Hz, 1H), 7.42 (dd, $J = 15.7, 7.8$ Hz, 2H), 7.33 (d, $J = 7.3$ Hz, 2H), 7.28 (t, $J = 7.5$ Hz, 2H), 7.22–7.16 (m, 3H), 7.15–7.10 (m, 3H), 5.18 (dd, $J = 12.3, 6.8$ Hz, 1H), 4.74 (td, $J = 8.4, 5.9$ Hz, 1H), 3.27 (dd, $J = 13.8, 4.7$ Hz, 1H), 3.13 (dd, $J = 13.9, 5.6$ Hz, 1H), 3.00 (ddd, $J = 13.7, 7.7, 5.9$ Hz, 2H). ^{13}C NMR (125

MHz, DMSO- d_6) δ 179.8, 170.5, 170.4, 140.3, 139.5, 137.3, 136.9, 130.1, 129.7, 129.6, 129.4, 129.0, 128.2, 127.9, 126.5, 126.3, 125.9, 125.2, 125.1, 123.1, 123.00, 122.9, 120.2, 119.9, 118.4, 115.5, 115.4, 57.5, 55.0, 37.5. ESI-HRMS m/z calcd for $C_{33}H_{28}F_6N_4O_2S$ $[M + Na]^+$: 681.1729; found: 681.1722.

2-(3-(3-Chlorophenyl)thioureido)-N-(1-((3,5-dimethylphenyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-phenylpropanamide (I-16). Yield 83.1%. Mp 139.6–147.2 °C. $[\alpha]_D^{20} = -37.0$ (c 0.1, AcOEt). 1H NMR (500 MHz, $CDCl_3$) δ 9.16 (d, $J = 33.1$ Hz, 2H), 8.69 (s, 1H), 7.63 (s, 1H), 7.43 (s, 1H), 7.24 (d, $J = 6.0$ Hz, 2H), 7.15 (s, 3H), 7.07 (s, 2H), 6.96 (s, 3H), 6.85 (s, 1H), 6.78 (d, $J = 6.8$ Hz, 5H), 5.44 (s, 1H), 5.12 (s, 1H), 3.19–2.96 (m, 2H), 2.90 (d, $J = 23.0$ Hz, 1H), 2.76 (s, 1H), 2.07 (s, 6H, $2 \times CH_3$). ^{13}C NMR (125 MHz, $CDCl_3$) δ 179.8, 171.0, 170.7, 139.7, 140.0, 139.0, 136.4, 136.2, 135.4, 134.3, 129.9, 129.6, 128.7, 128.3, 127.6, 127.2, 126.6, 125.6, 124.6, 122.9, 119.4, 59.1, 56.1, 39.24, 38.1, 21.2. ESI-HRMS m/z calcd for $C_{33}H_{33}ClN_4O_2S$ $[M + Na]^+$: 607.1905; found: 607.1900.

N-(4-Bromophenyl)-2-(2-(3-(3-bromophenyl)thioureido)-3-methylbutanamido)-3-methylpentanamide (I-20). Yield 88.2%. Mp 126.7–131.1 °C. $[\alpha]_D^{20} = -26.9$ (c 0.1, AcOEt). 1H NMR (400 MHz, DMSO- d_6) δ 10.21 (s, 1H), 9.88 (s, 1H), 8.25 (d, $J = 7.9$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.62–7.29 (m, 8H), 4.94 (s, 1H), 4.28 (t, $J = 8.0$ Hz, 1H), 2.12 (dd, $J = 12.7, 6.4$ Hz, 1H), 1.81 (d, $J = 5.4$ Hz, 1H), 1.54 (s, 1H), 1.24–1.06 (m, 1H), 0.85 (dd, $J = 16.8, 6.6$ Hz, 12H, $4 \times CH_3$). ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.4, 170.7, 170.3, 139.1, 138.2, 131.6, 131.5, 131.2, 131.1, 124.2, 121.2, 115.6, 114.9, 61.2, 58.1, 36.2, 31.2, 24.6, 18.9, 18.2, 15.3, 10.9. ESI-HRMS m/z calcd for $C_{24}H_{30}Br_2N_4O_2S$ $[M + K]^+$: 635.0088; found: 635.0080.

N-(3-Chloro-4-fluorophenyl)-2-(2-(3-(3,4-dichlorophenyl)thioureido)-3-methylbutanamido)-3-methylpentanamide (I-25). Yield 80.5%. Mp 129.5–133.2 °C. $[\alpha]_D^{20} = -21.8$ (c 0.1, AcOEt). 1H NMR (400 MHz, DMSO- d_6) δ 10.31 (s, 1H), 10.01 (s, 1H), 8.28 (d, $J = 8.0$ Hz, 1H), 8.16 (s, 1H), 7.98 (d, $J = 8.2$ Hz, 1H), 7.92 (dd, $J = 6.8, 2.3$ Hz, 1H), 7.53 (d, $J = 8.7$ Hz, 1H), 7.50–7.45 (m, 1H), 7.43 (dd, $J = 8.8, 2.3$ Hz, 1H), 7.35 (t, $J = 9.1$ Hz, 1H), 5.04–4.73 (m, 1H), 4.26 (t, $J = 8.1$ Hz, 1H), 2.13 (dd, $J = 12.8, 6.5$ Hz, 1H), 1.82 (d, $J = 6.2$ Hz, 1H), 1.53 (d, $J = 7.2$ Hz, 1H), 1.20–1.12 (m, 1H), 0.87 (dd, $J = 15.8, 8.4$ Hz, 12H, $4 \times CH_3$). ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.7, 171.1, 170.8, 154.8, 152.4, 140.4, 136.4, 130.8, 130.6, 125.5, 123.5, 122.4, 120.9, 117.5, 117.3, 61.7, 58.5, 36.6, 31.6, 25.0, 19.3, 18.6, 15.7, 11.2. ESI-HRMS m/z calcd for $C_{24}H_{28}Cl_3FN_4O_2S$ $[M + Na]^+$: 583.0875; found: 583.0870.

N-(1-((3-Chlorophenyl)amino)-3-methyl-1-oxobutan-2-yl)-3-methyl-2-(3-(3,4,5-trimethylphenyl)thioureido)pentanamide (I-30). Yield 83.6%. Mp 148.6–152.3 °C. $[\alpha]_D^{20} = -11.7$ (c 0.1, AcOEt). 1H NMR (400 MHz, $CDCl_3$) δ 8.72 (s, 1H), 8.26 (s, 1H), 7.59 (t, $J = 1.8$ Hz, 1H), 7.45 (s, 1H), 7.34 (d, $J = 8.2$ Hz, 1H), 7.13 (t, $J = 8.1$ Hz, 1H), 7.07–6.98 (m, 2H), 6.50 (s, 2H), 5.01 (t, $J = 7.7$ Hz, 1H), 4.43 (t, $J = 8.0$ Hz, 1H), 3.82 (s, 3H, CH_3), 3.74 (s, 6H, $2 \times CH_3$), 2.31–2.11 (m, 1H), 1.95–1.89 (m, 1H), 1.60–1.51 (m, 1H), 1.17–1.06 (m, 1H), 0.99 (dd, $J = 6.7, 2.9$ Hz, 6H, $2 \times CH_3$), 0.91–0.74 (m, 6H, $2 \times CH_3$). ^{13}C NMR (100 MHz, $CDCl_3$) δ 180.7, 172.1, 170.1, 153.9, 153.2, 138.6, 134.7, 130.1, 124.8, 120.3, 118.3, 103.6, 102.5, 63.1, 61.0, 60.2, 56.3, 56.2, 37.6, 30.5,

25.6, 19.5, 18.6, 15.4, 12.8, 11.4. ESI-HRMS m/z calcd for $C_{27}H_{37}ClN_4O_2S$ $[M + K]^+$: 555.1957; found: 555.2003.

1-(1-(1-(3,4-Dimethylphenylamino)-3-methyl-1-oxobutan-2-ylamino)-3-methyl-1-oxopentan-2-yl)-3-(3-nitrophenyl)thiourea (I-36). Yield 80.4%. Mp 194.5–195.4 °C. $[\alpha]_D^{20} = -22.7$ (c 0.1, AcOEt). 1H NMR (500 MHz, DMSO- d_6) δ 10.17 (s, 1H), 9.83 (d, $J = 20.0$ Hz, 1H), 8.85 (s, 1H), 8.14 (d, $J = 8.5$ Hz, 1H), 8.09 (d, $J = 8.4$ Hz, 1H), 7.90 (dd, $J = 8.2, 1.5$ Hz, 1H), 7.83 (d, $J = 7.4$ Hz, 1H), 7.57 (t, $J = 8.2$ Hz, 1H), 7.35 (s, 1H), 7.29 (dd, $J = 8.1, 1.9$ Hz, 1H), 7.03 (d, $J = 8.2$ Hz, 1H), 4.95 (t, $J = 7.4$ Hz, 1H), 4.27 (t, $J = 8.0$ Hz, 1H), 2.15 (d, $J = 10.6$ Hz, 6H), 2.04 (dd, $J = 14.2, 7.1$ Hz, 1H), 1.92–1.87 (m, 1H), 1.55–1.50 and 1.16–1.10 (m, 1H; m, 1H), 0.95–0.87 (m, 9H, $3 \times CH_3$), 0.85 (t, $J = 7.4$ Hz, 3H, CH_3). ^{13}C NMR (125 MHz, DMSO- d_6) δ 180.4, 170.7, 169.55, 147.5, 141.1, 136.5, 136.3, 131.1, 129.7, 129.6, 127.9, 120.6, 118.0, 116.9, 115.9, 61.0, 59.0, 37.4, 30.5, 24.6, 19.6, 19.2, 18.8, 18.6, 15.3, 11.3. ESI-HRMS m/z calcd for $C_{26}H_{35}N_5O_4S$ $[M - H]^-$: 512.2337; found: 512.2338.

4.3 Cytotoxicity assay

The cell lines MGC-803, NCI-H460, Hct-116, HepG2, SKOV-3, and HUVEC were obtained from the Shanghai Cell Bank in the Chinese Academy of Sciences. MGC-803, NCI-H460, Hct-116, HepG2, SKOV-3, and HUVEC cell lines were grown on 96-well microtitre plates at a cell density of 10×10^5 cells per well in DMEM medium with 10% FBS. DMEM and FBS were obtained from Gibco-Thermo (BRL Co. Ltd., USA). The plates were incubated at 37 °C in a humidified atmosphere of 5% CO_2 /95% air overnight. The cells were exposed to different concentrations of compounds I and 5-Fu, and incubated for another 48 h. The cells were stained with 10 μ L of MTT in an incubator for about 4 h. The medium was thrown away and replaced by 100 mL DMSO. The O.D. value was read at 570/630 nm using an enzyme labeling instrument.

4.4 Hoechst 33258 assay

NCI-H460 cells (2×10^6 cells) were seeded in six-well tissue culture plates and exposed to compound I-11 (10 μ M) for different times. The cells were fixed in 4% paraformaldehyde for 10 min, after which the medium was discarded. The cells were then washed twice with cold PBS and incubated with 0.5 mL of Hoechst 33258 (Beyotime, China) in the dark for 5 min. After 5 min incubation, the cells were washed twice with cold PBS and the results were analyzed using a Nikon ECLIPSETE2000-S fluorescence microscope using 350 nm excitation and 460 nm emissions.

4.5 Determination of mitochondrial membrane potential

The JC-1 probe (Beyotime, Haimen, China) was employed to measure mitochondrial depolarization in NCI-H460 cells. Briefly, NCI-H460 cells were seeded at the density of 2×10^6 cells mL^{-1} of the DMEM medium with 10% FBS on 6-well plates to the final volume of 2 mL. The plates were incubated overnight and then treated with compound I-11 (10 μ M) for different times. The JC-1 probe was added 20 min after replacing with fresh medium. Cells were collected at 2000 rpm, rinsed twice

with cold PBS and the mitochondrial membrane potential was analysed in the FL-1 channel by flow cytometry (FACS Aria II; BD, USA).

4.6 Apoptosis analysis

NCI-H460 cells were seeded at the density of 2×10^6 cells mL⁻¹ of the DMEM medium with 10% FBS on 6-well plates to the final volume of 2 mL. The plates were incubated overnight and then treated with different concentrations of compound **I-11** for 24 h. Briefly, after treatment with compound **I-11** for 24 h, cells were collected and washed twice with PBS, then resuspended in Binding Buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl₂) at a concentration of 1×10^6 cells mL⁻¹. The cells were subjected to 5 μ L of FITC Annexin V and 5 μ L of propidium iodide (PI) staining using the Annexin-V FITC apoptosis kit (BD, Pharmingen), followed by the transfer of 100 μ L of the solution to a 5 mL culture tube and incubating for 30 min in the dark at RT (25 °C). The apoptosis ratio was quantified by system software (CellQuest; BD Biosciences).

4.7 Cell cycle analysis

The NCI-H460 cell line was treated with different concentrations of compound **I-11**. After 48 h of incubation, cells were washed twice with ice-cold PBS, fixed and permeabilized with ice-cold 70% ethanol at -20 °C overnight. The cells were treated with 100 μ g mL⁻¹ RNase A at 37 °C for 30 min after washing with ice-cold PBS, and finally stained with 1 mg mL⁻¹ of propidium iodide (PI) (BD, Pharmingen) in the dark at 4 °C for 30 min. Analysis was performed with the system software (Cell Quest; BD Biosciences).

4.8 ROS assay

NCI-H460 cells were seeded into six-well plates and subjected to various treatments. Cells were collected and washed with PBS twice, then resuspended in 10 mM of DCFH-DA (Beyotime, Haimen, China) dissolved in cell free medium at 37 °C for 30 min in the dark, and then washed three times with PBS. Cellular fluorescence was quantified by flow cytometry at an excitation of 485 nm and an emission of 538 nm.

4.9 Calcium analysis

NCI-H460 cells were seeded into six-well plates and subjected to various treatments. The cells were collected and washed with PBS twice. Intracellular free Ca²⁺ levels in NCI-H460 cells were detected using the Ca²⁺ specific fluorescent probe, Fluo-3/AM (Beyotime, Haimen, China), for 40 min at 37 °C in PBS buffer. After loading with the Fluo-3 dye, cells were washed with PBS solution and cellular fluorescence was quantified using flow cytometry at wavelength of 515 nm.

4.10 Western blot

Total cell lysates from cultured NCI-H460 cells after compound **I-11** treatments, as mentioned earlier, were obtained by lysing the cells in ice-cold RIPA buffer with protease and phosphatase inhibitor, and storing at -20 °C for future use. The protein

concentrations were quantified by the Bradford method (BIO-RAD) using Multimode variscan instrument (Thermo Fisher Scientific). Equal amounts of protein per lane were applied in 12% SDS polyacrylamide gel for electrophoresis and transferred to the polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences). After the membrane was blocked at room temperature for 2 h in blocking solution, primary antibody was added and incubated at 4 °C overnight. Caspase-9, caspase-3, caspase-12, calpain, caspase-4, CHOP, GRP78, p-PERK and p-eIF2 α antibodies were purchased from Imgenex, USA. After three TBST washes, the membrane was incubated with the corresponding horseradish peroxidase-labeled secondary antibody (1 : 2000) (Santa Cruz) at room temperature for 1 h. Membranes were washed with TBST three times for 15 min and the protein blots were detected with chemiluminescence reagent (Thermo Fischer Scientific Ltd.). The X-ray films were developed with developer and fixed with fixer solution.

5 Statistics

The data were processed by the Student's *t*-test, with the significance level $P \leq 0.05$, using SPSS.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81260472 21362002 and 21431001), Special Research Found for the Doctoral Program of Higher Education (No. 20134504110002), State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Science and Technology of China (CMEMR2016-B06), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (No. 1107047002).

References

- (a) F. F. Tian, P. Zhou and Z. L. Li, *J. Mol. Struct.*, 2007, **830**, 106; (b) T. Day and S. A. Greenfield, *Exp. Brain Res.*, 2004, **155**, 500.
- Z. Qi, R. Verma, C. Gehring, Y. Yamaguchi, Y. Zhao, C. A. Ryan and G. A. Berkowitz, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 21193.
- A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, E. Vardy, X.-P. Huang, C. Trapella, R. Guerrini, G. Calo, B. L. Roth, V. Cherezov and R. C. Stevens, *Nature*, 2012, **485**, 395.
- K. Naka, Y. Jomen, K. Ishihara, J. Kim, T. Ishimoto, E.-J. Bae, R. P. Mohney, S. M. Stirdivant, H. Oshima, M. Oshima, D.-W. Kim, H. Nakauchi, Y. Takihara, Y. Kato, A. Ooshima and S.-J. Kim, *Nat. Commun.*, 2015, **6**, 8039.
- R. C. Kane, R. Dagher, A. Farrell, C. W. Ko, R. Sridhara, R. Justice and R. Pazdur, *Clin. Cancer Res.*, 2007, **13**, 5291.
- K. M. Kortuem and A. K. Stewart, *Blood*, 2013, **121**, 893.
- U. Vaishampayan, M. Glode, W. Du, A. Kraft, G. Hudes, J. Wright and M. Hussain, *Clin. Cancer Res.*, 2000, **6**, 4205.
- E. Kupperman, E. C. Lee, Y. Cao, B. Bannerman, M. Fitzgerald, A. Berger, J. Yu, Y. Yang, P. Hales,

- F. Bruzzese, J. Liu, J. Blank, K. Garcia, C. Tsu, L. Dick, P. Fleming, L. Yu, M. Manfredi, M. Rolfe and J. Bolen, *Cancer Res.*, 2010, **70**, 1970.
- 9 H. A. Lim, M. J. Y. Ang, J. Joy, A. Poulsen, W. Wu, S. C. Ching, J. Hill and C. S. B. Chia, *Eur. J. Med. Chem.*, 2013, **62**, 199.
- 10 H. Chen, C. Han, J. Wu, X. Liu, Y. Zhan, J. Chen, Y. Chen, R. Gu, L. Zhang, S. Chen, J. Jia, X. Zhen, L. T. Zheng and B. Jiang, *ACS Chem. Neurosci.*, 2016, **7**, 305.
- 11 X.-C. Huang, L. Jin, M. Wang, D. Liang, Z.-F. Chen, Y. Zhang, Y.-M. Pan and H.-S. Wang, *Eur. J. Med. Chem.*, 2015, **89**, 370.
- 12 J. D. Levenson, H. Zhang, J. Chen, S. K. Tahir, D. C. Phillips, J. Xue, P. Nimmer, S. Jin, M. Smith, Y. Xiao, P. Kovar, A. Tanaka, M. Bruncko, G. S. Sheppard, L. Wang, S. Gierke, L. Kategaya, D. J. Anderson, C. Wong, J. Eastham-Anderson, M. J. C. Ludlam, D. Sampath, W. J. Fairbrother, I. Wertz, S. H. Rosenberg, C. Tse, S. W. Elmore and A. J. Souers, *Cell Death Dis.*, 2015, **6**, e1590.
- 13 G. Silveira-Dorta, V. S. Martín and J. M. Padrón, *Amino Acids*, 2015, **47**, 1527.
- 14 B. Iovine, F. Guardia, C. Irace and M. A. Bevilacqua, *Biochimie*, 2016, **127**, 196.
- 15 Y. Shen, J. Yang, J. Li, X. Shi, L. Ouyang, Y. Tian and J. Lu, *PLoS One*, 2014, **9**, e104632.
- 16 M. Pandurangan, G. Enkhtaivan and D. H. Kim, *J. Mol. Recognit.*, 2016, **29**, 426.
- 17 J.-Z. Liu, B.-A. Song, H.-T. Fan, P. S. Bhadury, W.-T. Wan, S. Yang, W. Xu, J. Wu, L.-H. Jin, X. Wei, D.-Y. Hu and S. Zeng, *Eur. J. Med. Chem.*, 2010, **45**, 5108.
- 18 R. Ettari, C. Bonaccorso, N. Micale, C. Heindl, T. Schirmeister, M. L. Calabro, S. Grasso and M. Zappal, *ChemMedChem*, 2011, **6**, 1228.
- 19 S. K. Sharma, Y. Wu, N. Steinbergs, M. L. Crowley, A. S. Hanson, R. A. Casero Jr and P. M. Woster, *J. Med. Chem.*, 2010, **53**, 5197.
- 20 C. J. Hsiao, L. Tsia-Kun, Y. L. Chan, L. W. Hsin, C. H. Liao, C. H. Lee, P. C. Lyu and J. H. Guh, *Biochem. Pharmacol.*, 2008, **75**, 847.
- 21 S. Zitzmann, V. Ehemann and M. Schwab, *Cancer Res.*, 2002, **62**, 5139.
- 22 C. Monneret, *Eur. J. Med. Chem.*, 2001, **36**, 483.
- 23 D. Ravel, V. Dubois, J. Quinonero, F. Meyer-Losic, J. Delord, P. Rochaix, C. Nicolazzi, F. Ribes, C. Mazerolles, E. Assouly, K. Vialatte, I. Hor, J. Kearsey and A. Trouet, *Clin. Cancer Res.*, 2008, **15**, 1258.
- 24 K. Sidoryk, M. Switalska, J. Wietrzyk, A. Jaromin, M. Piętko-Ottlik, P. Cmoch, J. Zagrodzka, W. Szczeppek, Ł. Kaczmarek and W. Peczyńska-Czoch, *J. Med. Chem.*, 2012, **55**, 5077.
- 25 S. Shaaban, F. Sasse, T. Burkholz and C. Jacob, *Bioorg. Med. Chem.*, 2014, **22**, 3610.
- 26 B. Krust, D. E. Khoury, C. Soundaramourty, I. Nondier and A. G. Hovanesian, *Biochimie*, 2011, **93**, 426.
- 27 H. Q. Li, P. C. Lv, T. Yan and H. L. Zhu, *Anti-Cancer Agents Med. Chem.*, 2009, **9**, 471–480.
- 28 S. Saeed, N. Rashid, P. G. Jones, M. Ali and R. Hussain, *Eur. J. Med. Chem.*, 2010, **45**, 1323.
- 29 S. Y. Abbas, M. A. M. S. El-Sharief, W. M. Basyouni, I. M. I. Fakhr and E. W. El-Gammal, *Eur. J. Med. Chem.*, 2013, **64**, 111.
- 30 E. Tatar, S. Karakuş, Ş. G. Küçükgül, S. Ö. Okullu, N. Ünübol, T. Kocagöz, E. D. Clercq, G. Andrei, R. Snoeck, C. Pannecouque, S. Kalaycı, F. Şahin, D. Sriram, P. Yogeeswari and İ. Küçükgül, *Biol. Pharm. Bull.*, 2016, **39**, 502.
- 31 M.-H. Chen, Z. Chen, B.-A. Song, P. S. Bhadury, S. Yang, X.-J. Cai, D.-Y. Hu, W. Xue and S. Zeng, *J. Agric. Food Chem.*, 2009, **57**, 1383.
- 32 P. P. Dixit, V. J. Patil, P. S. Nair, S. Jain, N. Sinha and S. K. Arora, *Eur. J. Med. Chem.*, 2006, **41**, 423.
- 33 X. C. Huang, R. Z. Huang, Z. X. Liao, Y. M. Pan, S. H. Gou and H. S. Wang, *Eur. J. Med. Chem.*, 2016, **108**, 381.
- 34 S. Achilefu, H. N. Jimenez, R. B. Dorshow, J. E. Bugaj, E. G. Webb, R. R. Wilhelm, R. Rajagopalan, J. Johler and J. L. Erion, *J. Med. Chem.*, 2002, **45**, 2003.
- 35 C. Alemán, *J. Phys. Chem. A*, 2001, **105**, 6717.
- 36 A. G. Doyle and E. N. Jacobsen, *Chem. Rev.*, 2007, **107**, 5713.
- 37 P. Liu, C. Li, J. Zhang and X. Xu, *Synth. Commun.*, 2013, **43**, 3342.
- 38 J. K. Randal and D. M. Jyoti, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2014, **1843**, 2233–2239.
- 39 G. Nowak, *J. Biol. Chem.*, 2002, **277**, 43377.
- 40 H. U. Simon, A. H. Yehia and F. L. Schaffer, *Apoptosis*, 2000, **5**, 415.
- 41 J. M. David and O. Sten, *J. Leukocyte Biol.*, 1996, **59**, 775.
- 42 S. Orrenius, B. Zhivotovsky and P. Nicotera, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 552.
- 43 B. V. S. Reddy, K. Bhavani, A. Raju and J. S. Yadav, *Tetrahedron: Asymmetry*, 2011, **22**, 881.